about
Morphology and Species Composition of Southern Adriatic Sea Leptocephali Evaluated Using DNA BarcodingMonotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection.Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey.Could migraine be a "protective factor" against tumors?True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugsBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.ARTS (Aspiration-Retriever Technique for Stroke): Initial clinical experience.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Future directions in percutaneous vertebroplasty.Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'.Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.The route to personalized medicine in bladder cancer: where do we stand?Bladder cancer: molecular determinants of personalized therapy.Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.Kidney cancer and 2014: is innovation really over?Emerging concepts on drug resistance in bladder cancer: Implications for future strategies.New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials.Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Metabolic alterations in renal cell carcinoma.The origin of prostate metastases: emerging insights.Metabolic Alterations in Renal and Prostate Cancer.New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.Emerging Immunotargets in Metastatic Renal Cell Carcinoma.An Overview of Emerging Immunotargets of Genitourinary Tumors.Future perspectives for personalized immunotherapy in renal cell carcinoma.Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
P50
Q28818504-9F1A29B1-BB9B-435A-B9E7-F06719173E66Q33165559-717DD8C9-591A-40A4-919D-171D6B0BC7BAQ33429261-842654C2-5C86-48DB-985C-6CC5732C8C58Q34331571-DE68BEBA-A7AE-4414-8CE7-595CF316F56AQ34510256-92576D86-1925-473D-A9A9-D0E08294B9BEQ35083485-06BDF820-E906-4157-AF4C-59ADF39696D0Q35241042-021A8371-786F-4952-A633-602A4729DB64Q35653741-5579B6D1-56D2-4098-80B2-D656F33E3C90Q36081801-4AFB9F85-A932-4658-8067-C5FA0AAA495EQ36524946-4245F412-9EB2-45C0-8139-2487F128470BQ37173874-B7F13DD0-DB1E-4FA9-B0B5-83B8C0017412Q37335554-316211E7-B6A2-4EA7-A568-228580CC6ACAQ37530689-61244C1C-976F-43E9-97E7-46CCF046C7A4Q37688103-C57D0D20-56D8-4662-9336-A210CB8E4518Q38087648-00E27757-230F-4E4C-AD07-82774AAB16DAQ38153283-A7A48668-2DC3-41B4-A186-B0EE3AC41E82Q38153830-1A8ED8CB-51BE-4875-AA9E-6B672452EA60Q38170834-F8F2898E-43A4-408A-8C75-4BD121971493Q38177768-DFD93180-D356-4026-BAC2-A32CDF984936Q38312045-66826322-10AC-4BB3-A2C1-E6F31E93F8F5Q38317515-00323CAD-4E1C-4917-B752-F3C97ED68622Q38337192-ADDF4DD9-D273-4FF8-90AF-98507A18DF92Q38345252-2C9F0FEC-94F0-4651-A731-001E303E87AFQ38369000-B905B635-DF02-4A9B-A65A-C42F3E4CB66BQ38465870-51897AEE-B189-468E-8EC6-AF0D48E75C85Q38506739-76911683-D048-4DAA-B28A-7D9606CDA59FQ38513279-6C3A7207-B859-4601-94D1-4040E9FBFBB4Q38526607-99E03B8B-F6F2-49C4-A061-1C0C9E700067Q38527936-3935BD32-6C6A-4FB7-BA7C-ECB2A1CE90ACQ38541877-9016AD4D-9810-4FF3-BA2B-3BB0FAAB105BQ38545726-8273DB6B-9686-4123-ABC0-E8BB401419C8Q38546245-8ED312FF-66CE-43BF-BB62-6E080D388E98Q38585564-4263B98A-F3DF-4D4C-A09E-F51F4D750462Q38607173-A9596FD9-A26F-4383-BA3E-DDE584250BA5Q38632728-D2B5C191-C909-43BC-9AD2-0CEF8230771EQ38649833-6FB23D62-31C0-43B3-9511-1A3E553C751DQ38663122-388A5A90-4447-47EE-B675-54ABC497951FQ38663133-482562AA-0B7C-498B-A1D8-89491327FDEBQ38673583-F88CEAA1-961E-4E3A-9F19-BDB36CD4E698Q38684702-E5122CFB-91A3-428D-9BAC-7C24303F7821
P50
description
researcher
@en
name
F Massari
@en
F Massari
@nl
type
label
F Massari
@en
F Massari
@nl
prefLabel
F Massari
@en
F Massari
@nl
P106
P31
P496
0000-0001-6476-6871